Huntingtons Disease Topics
The On-Topic Netowork

Huntingtons Disease > Phase Ii Clinical Trial


Phase Ii Clinical Trial
Phase Ii Clinical Trial
Phase Ii Clinical Trial
Phase Ii Clinical Trial
Phase Ii Clinical Trial

The following information is about Phase Ii Clinical Trial.

Phase Ii Clinical Trial Defined

The second in a series of studies that test the safety and efficacy of a new drug or treatment in human participants and is only performed once the drug has successfully passed the phase I clinical trial. This study involves more participants and attempts to determine if the treatment has positive effects on the participants’ conditions. Side effects continue to be noted.

This definition is in context to Huntingtons Disease. See more contextual defintions for Phase Ii Clinical Trial.


Navigation: [ 1 2 3 4 5 Next ]

US crisis may hit Indian drug R and D

Published October 6, 2008, 1:34 pm, rediff.com

Stringent regulatory norms and the financial impact of the global credit crisis on some research companies may hurt half a dozen molecules of Indian companies, such as Glenmark, Nicholas Piramal and Ranbaxy Laboratories, that are close to launch, experts and analysts said.

Full Story


Advaxis Chief Executive Officer to Present at the 10th Annual World Vaccine Congress

Published October 6, 2008, 1:27 pm, Centre Daily Times

Advaxis Incorporated (OTCBB: ADXS) Chairman and CEO Tom Moore will present at this year's World Vaccine Congress 2008, being hosted at Le Palais des Congres de Lyon in Lyon, France. The Conference will be held October 6 - 9, 2008.

Full Story


Advaxis Chief Executive Officer to Present at the 10th Annual World Vaccine Congress

Published October 6, 2008, 1:18 pm, wallstreet:online AG

Advaxis Incorporated (173063;OTCBB:ADXS) Chairman and CEO Tom Moore will present at this year´s World

Full Story


Cortex's AMPAKINE Compound, CX717, Achieves Primary Endpoints In 2nd Phase IIa Respiratory Depression Study In Germany

Published October 6, 2008, 1:07 pm, Medical News Today

Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) reported that top-line data from its second Phase IIa study in opioid-induced respiratory depression (RD) demonstrated that a single oral dose of 1500mg of the AMPAKINE® compound CX717 achieved statistical significance (p = 0.

Full Story


Advaxis Chief Executive Officer to Present at the 10th Annual World Vaccine Congress

Published October 6, 2008, 1:05 pm, Business Wire via Yahoo! Finance

NEW BRUNSWICK, N.J.----Advaxis Incorporated Chairman and CEO Tom Moore will present at this year's World Vaccine Congress 2008, being hosted at Le Palais des Congres de Lyon in Lyon, France.

Full Story


Orexigen(R) Therapeutics Reviews Significant Data Regarding Its Obesity Product Candidates

Published October 6, 2008, 12:45 pm, PR Newswire via Yahoo! Finance

Orexigen Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced that the company reviewed in an oral presentation at The Obesity Society Annual Scientific Meeting that the investigational drug, Empatic , demonstrated up to 15% reduction in body weight of healthy obese people who completed 48-weeks ...

Full Story


Salix Presents New Phase II Data Evidence Demonstrating The Clinical Utility Of Rifaximin In Irritable Bowel Syndrome ...

Published October 6, 2008, 12:07 pm, Medical News Today

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced findings from two analyses of a Phase II clinical trial that demonstrate the utility of rifaximin, a non-absorbed, gut-selective antibiotic, in the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS).

Full Story


PanGenetics To Initiate Clinical Study Of CD40 Antagonist Antibody In Psoriatic Arthritis

Published October 6, 2008, 8:07 am, Medical News Today

PanGenetics B.V. announced today that the company has received formal regulatory approval to initiate clinical evaluation of the company's CD40 antagonist antibody, PG102. The multi-centre trial in Hungary and Serbia will recruit patients with active psoriatic arthritis, and is designed as a double blind, placebo controlled, single ascending dose study.

Full Story


Parkinson's Disease Latest Update: Market upgrade following evidence of disease slowing with Azilect

Published October 6, 2008, 7:18 am, Marketwire via Yahoo! Finance

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue.

Full Story


Award-Winning Short Film on Pediatric Clinical Research Provides Parents with Answers

Published October 6, 2008, 6:59 am, Centre Daily Times

New England Research Institutes, Inc. (NERI), and the National Heart, Lung, and Blood Institute (NHLBI) today announced that their short film, No More Hand Me Downs: Research Designed for Children, has been awarded three Telly Awards in the categories of Children's Health, Medical Education and General Interest. NERI and the NHLBI partnered to produce the 10-minute film to provide reliable and ...

Full Story


Navigation: [ 1 2 3 4 5 Next ]

Are you looking for additional Huntingtons Disease > Phase Ii Clinical Trial news? Try our new "Phase Ii Clinical Trial News Focus" area.

Social bookmarks are not available at the moment.

If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Phase Ii Clinical Trial. If you would like to find related tags we recommend Tag Patterns > Phase Ii Clinical Trial

Off-site Phase Ii Clinical Trial Research Links

If you still need additional information on Phase Ii Clinical Trial then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Huntingtons Disease

If you know the Huntingtons Disease Term Name use the links below to quickly jump to your desired focus.



Bookmark Us

The On Topic Network

This website is part of The On Topic Network.

Thank You

Huntingtons-Disease.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.

Best Viewed With

License

Creative Commons License This work is licensed under Creative Commons.




Powered by Odin Assemble 2.5a